ArticleVirology2025
Cross-protection against St. Louis encephalitis virus and Usutu virus by West Nile virus convalescent plasma.
Article in Virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Global Systematic Review on the Potential of Metal-Based Nanoparticles in the Fight Against Mosquito Vectors.Journal of tropical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
West Nile virus (WNV), Usutu virus (USUV), and Saint Louis encephalitis virus (SLEV) are emerging mosquito-borne flaviviruses within the Japanese encephalitis virus serocomplex. They share a similar transmission cycle between passerine birds and Culex spp. mosquitoes, and their spillover can cause neuroinvasive diseases among humans and animals. Individuals might be exposed to more than one of these viruses during their lifetime. Previously, we found that WNV vaccination protected mice from USUV disease, and sera collected from the WNV vaccinated mice cross-neutralized USUV in vitro. However, whether WNV convalescent (post-recovery) plasma cross-protects against heterologous SLEV or USUV infection is unknown. In this study, in vivo experiments were conducted to assess whether WNV human convalescent plasma and/or mouse convalescent serum afforded protection to mice against SLEV and USUV infection and neuroinvasion. First, we found that human and mouse WNV convalescent samples cross-neutralized USUV and SLEV in vitro. We then passively transferred human or mouse WNV convalescent samples into mice and challenged them with WNV, USUV, or SLEV. Both human and mouse WNV convalescent samples reduced WNV neuroinvasion and SLEV and USUV viremia during acute infection. Mouse WNV convalescent serum significantly reduced SLEV titers in the brain and showed a trend towards resulting in less inflammation in the brain. These findings helped to better understand the potential cross-protection among WNV, SLEV, and USUV, and identified cross-neutralizing antibodies as potential correlates of protection for individuals exposed to multiple flaviviruses, though protection was incomplete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.